Iterum Therapeutics plc ITRMF · Stock Open Iterum Therapeutics plc in new tab
Iterum Therapeutics plc Analysis (ITRMF)
Is Iterum Therapeutics plc a good investment? Iterum Therapeutics plc (ITRMF) is currently trading at 0.0350 USD.
Earnings Schedule: Iterum Therapeutics plc is expected to release its next earnings report on June 16, 2026.
Investor FAQ
Does Iterum Therapeutics plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Iterum Therapeutics plc?
Iterum Therapeutics plc is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be June 16, 2026. The company currently has a trailing EPS of -0.72.
Company Profile
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics plc is in reorganization.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 18, 2022 | 0.066667 |
| Aug. 18, 2022 | 0.070000 |
Community Discussion